<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02830204</url>
  </required_header>
  <id_info>
    <org_study_id>016-100</org_study_id>
    <nct_id>NCT02830204</nct_id>
  </id_info>
  <brief_title>Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study</brief_title>
  <acronym>SITRAL</acronym>
  <official_title>Surgical Implantation of TRAnscatheter vaLve in Native Mitral Annular Calcification (SITRAL) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Baylor Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Edwards Lifesciences</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Baylor Research Institute</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to establish the safety and feasibility of the Edwards SAPIEN 3&#xD;
      valve in subjects with mitral annular calcification (MAC) associated with mitral stenosis&#xD;
      (MS) and/or mitral regurgitation who are at high-risk for mitral valve surgery or deemed&#xD;
      inoperable due to the extent of calcification.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Technical Success:&#xD;
&#xD;
      Alive, with&#xD;
&#xD;
        -  Successful access, delivery and retrieval of the device delivery system, and&#xD;
&#xD;
        -  Deployment and correct positioning (including repositioning/recapture if needed) of the&#xD;
           single intended device, and&#xD;
&#xD;
        -  No need for additional unplanned or emergency surgery or re-intervention related to the&#xD;
           device or access procedure&#xD;
&#xD;
      Device Success:&#xD;
&#xD;
      Alive and stroke free, with&#xD;
&#xD;
        -  Original intended device in place, and&#xD;
&#xD;
        -  No additional surgical or interventional procedures related to access or the device&#xD;
           since completion of the original procedure (i.e., exit from the cath lab/Operating&#xD;
           Room(OR)), and&#xD;
&#xD;
        -  Intended performance of the device:&#xD;
&#xD;
             -  Structural performance: No migration, embolization, detachment, fracture,&#xD;
                hemolysis, thrombosis (including reduced leaflet motion) or endocarditis, etc, and&#xD;
&#xD;
             -  Hemodynamic performance: Maintenance of relief of stenosis or insufficiency without&#xD;
                producing the opposite (Stenosis = Mitral Valve Area (MVA) &lt; 1.5cm2 and Mitral&#xD;
                Valve (MV) gradient &gt; 5mmHg, Insufficiency = Mitral Regurgitation (MR) &gt;1+), and&#xD;
&#xD;
             -  Absence of para-device complications (e.g., Paravalvular Leak (PVL) &gt; mild, need&#xD;
                for a Permanent Pacemaker (PPM), erosion, Annular rupture or Aortic Valve (AV)&#xD;
                Groove disruption, Left Ventricular Outflow Tract (LVOT) gradient increase &gt;&#xD;
                10mmHg)&#xD;
&#xD;
      Procedural Success:&#xD;
&#xD;
      Device success, and&#xD;
&#xD;
        -  No device or procedure related Serious Adverse Events (SAEs) (Life threatening bleed;&#xD;
           major vascular or cardiac structural complications requiring unplanned reintervention or&#xD;
           surgery; stage 2 or 3 Acute Kidney Injury (includes new dialysis); Myocardial Infarction&#xD;
           (MI) or need for percutaneous coronary intervention (PCI)/coronary artery bypass graft&#xD;
           (CABG); severe heart failure (HF) or hypotension requiring intravenous (IV) inotrope,&#xD;
           ultrafiltration or mechanical circulatory support; prolonged intubation ( &gt; 48 hours)&#xD;
&#xD;
      6.2 Secondary objective(s)&#xD;
&#xD;
      Device Success (at 6 months and 1 year)&#xD;
&#xD;
        -  Subject success 1 year&#xD;
&#xD;
      Device Success:&#xD;
&#xD;
      Alive and stroke free, with&#xD;
&#xD;
        -  Original intended device in place, and&#xD;
&#xD;
        -  No additional surgical or interventional procedures related to access or the device&#xD;
           since completion of the original procedure (i.e., exit from the cath lab/Operating Room&#xD;
           (OR)), and&#xD;
&#xD;
        -  Intended performance of the device:&#xD;
&#xD;
             -  Structural performance: No migration, embolization, detachment, fracture,&#xD;
                hemolysis, thrombosis (including reduced leaflet motion) or endocarditis, etc, and&#xD;
&#xD;
             -  Hemodynamic performance: Maintenance of relief of stenosis or insufficiency without&#xD;
                producing the opposite (Stenosis = MVA &lt; 1.5cm2 and MV gradient &gt; 5mmHg,&#xD;
                Insufficiency = MR &gt;1+), and&#xD;
&#xD;
             -  Absence of para-device complications (e.g., PVL &gt; mild, need for a PPM, erosion,&#xD;
                Annular rupture or AV Groove disruption, LVOT gradient increase &gt; 10mmHg)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 2016</start_date>
  <completion_date type="Anticipated">December 2022</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Procedural success</measure>
    <time_frame>30 days</time_frame>
    <description>Procedural Success is defined as:&#xD;
Device success, and&#xD;
No device or procedure related serious adverse events (SAEs) (Life threatening bleed; major vascular or cardiac structural complications requiring unplanned reintervention or surgery; stage 2 or 3 acute kidney injury (AKI) (includes new dialysis); myocardial infarction (MI) or need for percutaneous coronary intervention (PCI)/coronary artery bypass graft (CABG); severe heart failure (HF) or hypotension requiring intravenous (IV) inotrope, ultrafiltration or mechanical circulatory support; prolonged intubation ( &gt; 48 hours)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Technical success</measure>
    <time_frame>Procedure Stop Time</time_frame>
    <description>Technical Success is defined as:&#xD;
Alive, with&#xD;
Successful access, delivery and retrieval of the device delivery system, and&#xD;
Deployment and correct positioning (including repositioning/recapture if needed) of the single intended device, and&#xD;
No need for additional unplanned or emergency surgery or re-intervention related to the device or access procedure</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Device success</measure>
    <time_frame>30 days</time_frame>
    <description>Device Success is defined as:&#xD;
Alive and stroke free, with&#xD;
Original intended device in place, and&#xD;
No additional surgical or interventional procedures related to access or the device since completion of the original procedure (i.e., exit from the cath lab/operating room (OR)), and&#xD;
Intended performance of the device:&#xD;
Structural performance: No migration, embolization, detachment, fracture, hemolysis, thrombosis (including reduced leaflet motion) or endocarditis, etc, and&#xD;
Hemodynamic performance: Maintenance of relief of stenosis or insufficiency without producing the opposite (Stenosis = mitral valve area (MVA) &lt; 1.5cm2 and mitral valve (MV) gradient &gt; 5mmHg, Insufficiency = mitral regurgitation (MR) &gt;1+), and&#xD;
Absence of para-device complications (e.g., paravalvular leak (PVL) &gt; mild, need for a permanent pacemaker (PPM), erosion, Annular rupture or aortic valve (AV) Groove disruption, left ventricular outflow tract (LVOT) gradient increase &gt; 10mmHg)</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Device success</measure>
    <time_frame>6 months</time_frame>
    <description>Device Success is defined as:&#xD;
Alive and stroke free, with&#xD;
Original intended device in place, and&#xD;
No additional surgical or interventional procedures related to access or the device since completion of the original procedure (i.e., exit from the cath lab/operating room (OR)), and&#xD;
Intended performance of the device:&#xD;
Structural performance: No migration, embolization, detachment, fracture, hemolysis, thrombosis (including reduced leaflet motion) or endocarditis, etc, and&#xD;
Hemodynamic performance: Maintenance of relief of stenosis or insufficiency without producing the opposite (Stenosis = MVA &lt; 1.5cm2 and MV gradient &gt; 5mmHg, Insufficiency = MR &gt;1+), and&#xD;
Absence of para-device complications (e.g., PVL &gt; mild, need for a PPM, erosion, Annular rupture or AV Groove disruption, LVOT gradient increase &gt; 10mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Device Success</measure>
    <time_frame>1 year</time_frame>
    <description>Device Success is defined as:&#xD;
Alive and stroke free, with&#xD;
Original intended device in place, and&#xD;
No additional surgical or interventional procedures related to access or the device since completion of the original procedure (i.e., exit from the cath lab/OR), and&#xD;
Intended performance of the device:&#xD;
Structural performance: No migration, embolization, detachment, fracture, hemolysis, thrombosis (including reduced leaflet motion) or endocarditis, etc, and&#xD;
Hemodynamic performance: Maintenance of relief of stenosis or insufficiency without producing the opposite (Stenosis = MVA &lt; 1.5cm2 and MV gradient &gt; 5mmHg, Insufficiency = MR &gt;1+), and&#xD;
Absence of para-device complications (e.g., PVL &gt; mild, need for a PPM, erosion, Annular rupture or AV Groove disruption, LVOT gradient increase &gt; 10mmHg)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Subject success</measure>
    <time_frame>1 year</time_frame>
    <description>Subject Success is defined as:&#xD;
All of the following must be present:&#xD;
I. Device success (either optimal or acceptable), and II. Patient returned to the pre-procedural setting: and III. No rehospitalizations or reinterventions for the underlying condition (e.g., mitral regurgitation, heart failure); and IV. Improvement from baseline in symptoms (e.g., NYHA improvement by &gt; or = 1 functional class); and V. Improvement from baseline in functional status (e.g., 6-min walk test improvement by &gt; or = 50 m); and VI. Improvement from baseline in quality-of-life (e.g., Kansas City Cardiomyopathy Questionnaire improvement by &gt; or = 10)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Mitral Annular Calcification</condition>
  <arm_group>
    <arm_group_label>Mitral Valve Replacement with Sapien3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>subjects with surgical MVR with Sapien3</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Mitral Valve Replacement with Sapien3</intervention_name>
    <description>subjects with surgical MVR with Sapien3</description>
    <arm_group_label>Mitral Valve Replacement with Sapien3</arm_group_label>
    <other_name>MVR</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Subject has severe native mitral annular calcification associated with mitral stenosis&#xD;
             and/or regurgitation. Qualifying echo must be within 60 days of the date of the&#xD;
             procedure.&#xD;
&#xD;
          -  Subject has a clinical indication for mitral valve replacement, as demonstrated by&#xD;
             reported New York Heart Association (NYHA) Functional Class II or greater.&#xD;
&#xD;
          -  The subject is at least 22 years old.&#xD;
&#xD;
          -  The Heart Team agrees that the subject is high risk or inoperable for surgical mitral&#xD;
             valve repair or replacement (MVR), based on a conclusion that the probability of death&#xD;
             or serious, irreversible morbidity exceeds the probability of meaningful improvement.&#xD;
             The following concomitant procedures, are allowed: MAZE, Tricuspid Valve Procedures&#xD;
             (TVP), and Atrial Fibrillation (AF) ablation, coronary artery bypass grafting and&#xD;
             septal myectomy.&#xD;
&#xD;
          -  The study subject has been informed of the nature of the study, agrees to its&#xD;
             provisions and has provided written informed consent as approved by the Institutional&#xD;
             Review Board (IRB) of the respective clinical site.&#xD;
&#xD;
          -  The study subject agrees to comply with all required post-procedure follow-up visits&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Evidence of an acute myocardial infarction (MI) ≤ 30 days before the intended&#xD;
             treatment [defined as: Q wave MI, or non-Q wave MI with total CK elevation of CK-MB ≥&#xD;
             twice normal in the presence of MB elevation and/or troponin level elevation (WHO&#xD;
             definition)].&#xD;
&#xD;
          -  Any therapeutic invasive cardiac procedure resulting in a permanent implant that is&#xD;
             performed within 30 days of the index procedure (unless part of planned strategy for&#xD;
             treatment of concomitant coronary artery disease).&#xD;
&#xD;
          -  Leukopenia (white blood cell count &lt; 2000 cell/mL), acute anemia (hemoglobin &lt; 8&#xD;
             g/dL), or thrombocytopenia (platelet count &lt; 50,000 cell/mL).&#xD;
&#xD;
          -  Hemodynamic or respiratory instability requiring vasoactive medications, mechanical&#xD;
             ventilation at time of procedure.&#xD;
&#xD;
          -  Need for emergency surgery for any reason.&#xD;
&#xD;
          -  Severe left ventricular dysfunction with Left Ventricular Ejection Fraction (LVEF) &lt;&#xD;
             30%.&#xD;
&#xD;
          -  Severe right ventricular dysfunction&#xD;
&#xD;
          -  Pregnancy, lactation, or planning to become pregnant&#xD;
&#xD;
          -  Echocardiographic evidence of left ventricular mass, thrombus, or concerns of active&#xD;
             infective endocarditis.&#xD;
&#xD;
          -  Active upper gastrointestinal (GI) bleeding within 3 months prior to procedure without&#xD;
             treatment or 30 days prior to procedure with definitive treatment.&#xD;
&#xD;
          -  A known contraindication or hypersensitivity to all anticoagulation regimens, or&#xD;
             inability to be maintained on oral anticoagulant following the study procedure.&#xD;
&#xD;
          -  End stage renal disease requiring dialysis&#xD;
&#xD;
          -  Clinically (by neurologist) or neuroimaging confirmed stroke or transient ischemic&#xD;
             attack (TIA) within 30 days of the procedure.&#xD;
&#xD;
          -  Estimated life expectancy &lt; 12 months&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>22 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Robert Smith, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Baylor Research Institute</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Megan White, M.S</last_name>
    <phone>469-814-4181</phone>
    <email>Megan.White1@bswhealth.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristen Chionh, M.S.</last_name>
    <phone>469-814-4736</phone>
    <email>Kristen.chionh@bswhealth.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>St. Vincent Heart Center</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46290</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jana Fisher, RN, BSN</last_name>
      <phone>317-583-7804</phone>
      <email>Jana.Fisher@ascension.org</email>
    </contact>
    <investigator>
      <last_name>David Heimansohn, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>MHRI Maryland</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rachel Campbell</last_name>
    </contact>
    <investigator>
      <last_name>Brian Bethea</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Icahn School of Medicine at Mount Sinai</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10029</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <name>Lankenau Institute for Medical Research</name>
      <address>
        <city>Wynnewood</city>
        <state>Pennsylvania</state>
        <zip>19096</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sherry McDermott</last_name>
      <phone>484-476-8514</phone>
      <email>McDermottS@mlhs.org</email>
    </contact>
    <investigator>
      <last_name>Scott Goldman, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Baylor College of Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carmen Moore</last_name>
    </contact>
    <investigator>
      <last_name>Kenneth Liao</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Heart Hospital Baylor Plano</name>
      <address>
        <city>Plano</city>
        <state>Texas</state>
        <zip>75093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Megan White</last_name>
      <phone>469-814-4181</phone>
      <email>megan.white1@bswhealth.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22903</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2020</verification_date>
  <study_first_submitted>May 4, 2016</study_first_submitted>
  <study_first_submitted_qc>July 8, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 12, 2016</study_first_posted>
  <last_update_submitted>January 26, 2021</last_update_submitted>
  <last_update_submitted_qc>January 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">January 28, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>mitral valve regurgitation</keyword>
  <keyword>mitral valve stenosis</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Calcinosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>There is currently no plan to share individual participant data</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

